Skip to main content
Fig. 3 | BMC Cardiovascular Disorders

Fig. 3

From: Uncertainty on the effectiveness and safety of rivaroxaban in premenopausal women with atrial fibrillation: empirical evidence needed

Fig. 3

Tornado plot: Overview of the impact of the main health outcomes on decision uncertainty. The figure shows the impact of the current uncertainty on the relative risks (RRs) of rivaroxaban vs. Vitamin K Antagonists (VKAs) in premenopausal women with atrial fibrillation on Quality Adjusted Life Years (QALYs). For example, the RR of ischemic stroke with rivaroxaban vs. VKAs in premenopausal women currently ranges from 0.66 to 1.37. When the RR is 1.37, treatment with rivaroxaban leads to a loss of −0.32 QALYs. If the RR is 0.66, treatment with rivaroxaban leads to a gain of 1.69 QALYs

Back to article page

BMC Cardiovascular Disorders

ISSN: 1471-2261

Contact us